Paxneury and Tuzulby should be granted Europe-wide marketing authorizations for treating attention-deficit hyperactivity, the ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines ...

Roche (RHHBY) announced that the European Medicines Agency, EMA, has approved Vabysmo 6.0 mg single-dose prefilled syringe, ...

Geron (GERN) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a ...

announced that tobevibart and elebsiran have received US Food and Drug Administration breakthrough therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for ...

EMA approves Roche’s Vabysmo prefilled syringe for three retinal conditions that can cause blindness: Basel Saturday, December 14, 2024, 10:00 Hrs [IST] Roche announced that the ...

Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has announced that the ...

A few days ago, the European Medicines Agency approved a new drug to delay or slow down the progression of Alzheimer's ...

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis ...

Separately, upon receipt of the full efficacy and safety results for the NORSE EIGHT clinical trial in the United States, which are expected in January 2025, Outlook Therapeutics plans to resubmit its ...

Indianapolis: Eli Lilly and Company has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Outlook Therapeutics said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European ...